Background
Background About 30% of people About 30% of people with depression do not respond to an with depression do not respond to an antidepressant atthe recommended dose antidepressant atthe recommended dose and can be described as having treatmentand can be described as having treatmentrefractory depression. refractory depression.
Aims Aims To summarise the findings from all
To summarise the findings from all randomised controlled trials (RCTs) that randomised controlled trials (RCTs) that have assessed the efficacy of a have assessed the efficacy of a pharmacological or psychological pharmacological or psychological intervention for treatment-refractory intervention for treatment-refractory depression. depression.
Method Method We used a systematic search
We used a systematic search strategy to identify RCTs that included strategy to identify RCTs that included adults aged18^75 years with a diagnosis of adults aged18^75 years with a diagnosis of unipolar depression that had not unipolar depression that had not responded to a 4-weekcourse of a responded to a 4-weekcourse of a recommended dose of an antidepressant. recommended dose of an antidepressant.
Results
Results We identified16 RCTs.None of We identified16 RCTs.None of the included trials assessed the efficacy of the included trials assessed the efficacy of psychotherapy. Allthe trials were too small psychotherapy. Allthe trials were too small to detect an important clinical response. to detect an important clinical response. We found only two trials on lithium We found only two trials on lithium augmentation, which randomised 50 augmentation, which randomised 50 subjects in total. subjects in total.
Conclusions Conclusions There is little evidence to
There is little evidence to guide the management of depression that guide the management of depression that has not responded to a course of has not responded to a course of antidepressants.Treatment-refractory antidepressants.Treatment-refractory depression is an important public health depression is an important public health problem and large pragmatic trials are problem and large pragmatic trials are needed to inform clinical practice. needed to inform clinical practice.
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Approximately 30% of people with depresApproximately 30% of people with depressive illness do not respond to the usual sive illness do not respond to the usual recommended dose of antidepressants. recommended dose of antidepressants. The World Psychiatric Association made The World Psychiatric Association made one of the earliest definitions of 'resistant' one of the earliest definitions of 'resistant' depression as, ' an absence of clinical depression as, 'an absence of clinical response to treatment with a tricyclic antiresponse to treatment with a tricyclic antidepressant at a minimum dose of 150 mg/ depressant at a minimum dose of 150 mg/ day of imipramine (or equivalent drug) for day of imipramine (or equivalent drug) for 4 to 6 weeks' (World Psychiatric Asso-4 to 6 weeks' (World Psychiatric Association, 1974) . A number of alternative ciation, 1974) . A number of alternative definitions have been used but the term definitions have been used but the term 'treatment-refractory depression' that we 'treatment-refractory depression' that we adopt here will be the World Psychiatric adopt here will be the World Psychiatric Association definition with a 4-week time Association definition with a 4-week time criterion. Most other definitions require criterion. Most other definitions require more 'severe' treatment-refractory depresmore 'severe' treatment-refractory depression, in the sense that patients have failed sion, in the sense that patients have failed to respond to more than a single course of to respond to more than a single course of antidepressant (Thase & Rush, 1995) . antidepressant (Thase & Rush, 1995) .
Current guidance Current guidance
There is little current guidance on the There is little current guidance on the management of treatment-refractory demanagement of treatment-refractory depression. Current guidelines (American pression. Current guidelines (American Psychiatric Association, 1993; Anderson Psychiatric Association, 1993; Anderson et et al al, 2000) suggest increasing the dose of , 2000) suggest increasing the dose of antidepressant, switching to a different antidepressant, switching to a different class, adding psychotherapy or augmenting class, adding psychotherapy or augmenting with lithium or electroconvulsive treatwith lithium or electroconvulsive treatment. The lack of guidance is reflected by ment. The lack of guidance is reflected by variation in the management of treatmentvariation in the management of treatmentrefractory depression. A third of psychiarefractory depression. A third of psychiatrists in the north-east of the USA preferred trists in the north-east of the USA preferred lithium augmentation (Nierenberg & lithium augmentation (Nierenberg & White, 1990) . Canadian psychiatrists White, 1990) . Canadian psychiatrists (Chaimowitz (Chaimowitz et al et al, 1991) had an equal pre-, 1991) had an equal preference for a second tricyclic, augmentation ference for a second tricyclic, augmentation with a monoamine oxidase inhibitor and with a monoamine oxidase inhibitor and augmentation with lithium. The most popaugmentation with lithium. The most popular choice in the UK (Shergill & Katona, ular choice in the UK (Shergill & Katona, 1996) was to increase the dose or to change 1996) was to increase the dose or to change class. However, 39% of respondents in this class. However, 39% of respondents in this study stated that they were not confident study stated that they were not confident when treating this condition. when treating this condition.
Previous systematic reviews Previous systematic reviews Systematic reviews of the literature attempt Systematic reviews of the literature attempt to provide an unbiased and succinct sumto provide an unbiased and succinct summary of all of the available evidence and, mary of all of the available evidence and, when possible, produce a meta-analysis when possible, produce a meta-analysis that summarises results more precisely that summarises results more precisely (Chalmers & Altman, 1995; Lewis (Chalmers & Altman, 1995; Lewis et al et al, , 1997) . Previous systematic reviews have 1997). Previous systematic reviews have assessed the efficacy of lithium augmentassessed the efficacy of lithium augmentation (Austin ation (Austin et al et al, 1991; Bauer & , 1991; Bauer & Dopfmer, 1999) and triiodothyronine Dopfmer, 1999) and triiodothyronine augmentation (Aronson augmentation (Aronson et al et al, 1996) . The , 1996) . The systematic review of Austin systematic review of Austin et al et al included included 5 trials, but 4 of these used only 3 weeks 5 trials, but 4 of these used only 3 weeks to define treatment resistance. One of the to define treatment resistance. One of the trials treated subjects with lithium for only trials treated subjects with lithium for only 48 hours, and another reported very low 48 hours, and another reported very low (less than 0.3 mmol/l) blood lithium levels. (less than 0.3 mmol/l) blood lithium levels. Bauer & Dopfmer (1999) included ranBauer & Dopfmer (1999) included randomised controlled trials (RCTs) in their domised controlled trials (RCTs) in their review that studied both unipolar and review that studied both unipolar and bipolar depression. It would seem unwise bipolar depression. It would seem unwise to generalise from patients with bipolar deto generalise from patients with bipolar depression to those with unipolar depression, pression to those with unipolar depression, especially in relation to lithium use. The especially in relation to lithium use. The systematic review of four randomised systematic review of four randomised double-blind studies of triiodothyronine double-blind studies of triiodothyronine (Aronson (Aronson et al et al, , 1996 ) also included studies 1996) also included studies that used a that used a 3-week criterion and patients 3-week criterion and patients with bipolar depression. with bipolar depression.
The aim of this systematic review was The aim of this systematic review was to identify and summarise all the RCTs that to identify and summarise all the RCTs that had investigated the pharmacological and had investigated the pharmacological and psychological management of patients with psychological management of patients with treatment-refractory depression. treatment-refractory depression.
METHOD METHOD
A literature search was carried out in A literature search was carried out in association with the Cochrane Collaborassociation with the Cochrane Collaboration (Depression, Anxiety and Neurosis ation (Depression, Anxiety and Neurosis Group). The Cochrane Controlled Trials Group). The Cochrane Controlled Trials register (CCTR) 2000 edition was searched, register (CCTR) 2000 edition was searched, as were the following electronic databases: as were the following electronic databases: E EMBASE MBASE (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , Medline (1966 Medline ( -(1980 Medline ( -1999 , Medline (1966 Medline ( -1999 , Psychlit and PsychInfo (1974-1999) , Psychlit and PsychInfo (1974-1999) , LILACS (1982 LILACS ( -1999 . The standard 1999), LILACS (1982 LILACS ( -1999 and COMBIN*. The COMBIN*. The abstracts of these trials were read to abstracts of these trials were read to identify those that appeared to reach the identify those that appeared to reach the inclusion criteria. Paper or electronic copies inclusion criteria. Paper or electronic copies 2 8 4 2 8 4 of trials that appeared, from the abstract, to of trials that appeared, from the abstract, to achieve the inclusion criteria were collected achieve the inclusion criteria were collected for further inspection. for further inspection. When the search strategy had been When the search strategy had been completed, the authors of all identified completed, the authors of all identified trials (both those to be included and the trials (both those to be included and the 'near misses') and all known experts in 'near misses') and all known experts in the field were contacted for any further inthe field were contacted for any further information on trials that were unpublished, formation on trials that were unpublished, in press or were currently in progress. If in press or were currently in progress. If trials presented data on both unipolar and trials presented data on both unipolar and bipolar depression the authors were asked bipolar depression the authors were asked for the results of the unipolar participants. for the results of the unipolar participants.
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Inclusion criteria Inclusion criteria
Randomised controlled trials were included Randomised controlled trials were included in the review if the participants had a diagin the review if the participants had a diagnosis of unipolar depression that had not nosis of unipolar depression that had not responded to a minimum of 4 weeks of responded to a minimum of 4 weeks of antidepressant treatment at a recommended antidepressant treatment at a recommended dose (at least 150 mg/day imipramine or dose (at least 150 mg/day imipramine or equivalent). This definition was chosen in equivalent). This definition was chosen in order to include as much evidence as order to include as much evidence as possible. Trials that concentrated solely on possible. Trials that concentrated solely on patient groups either under the age of 18 patient groups either under the age of 18 years or over the age of 75 years were exyears or over the age of 75 years were excluded, as were trials including patients cluded, as were trials including patients with comorbid schizophrenia. Participants with comorbid schizophrenia. Participants with bipolar disorder were excluded. These with bipolar disorder were excluded. These criteria and the details of the search criteria and the details of the search strategy were decided before beginning the strategy were decided before beginning the review and published as a protocol in the review and published as a protocol in the Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews (Stimpson (Stimpson et al et al, 2000) . , 2000). Summary data from each of the identiSummary data from each of the identified trials were extracted independently by fied trials were extracted independently by at least two of the three reviewers and at least two of the three reviewers and entered onto predesigned data extraction entered onto predesigned data extraction forms. Any disagreements were discussed forms. Any disagreements were discussed until a consensus was reached. If additional until a consensus was reached. If additional information was needed the first author of information was needed the first author of the trials was contacted. the trials was contacted.
Statistical methods Statistical methods
Where possible we planned to carry out Where possible we planned to carry out meta-analysis of the results from trials. meta-analysis of the results from trials. We wished to use a dichotomous outcome, We wished to use a dichotomous outcome, the numbers who had 'recovered'. This is the numbers who had 'recovered'. This is usually reported as a 50% reduction in usually reported as a 50% reduction in Hamilton Rating Scale for Depression Hamilton Rating Scale for Depression (HRSD) scores (Hamilton, 1960) . This out-(HRSD) scores (Hamilton, 1960) . This outcome was chosen for two main reasons. come was chosen for two main reasons. First, it avoids the difficulty of establishing First, it avoids the difficulty of establishing whether a continuous variable has a normal whether a continuous variable has a normal distribution. Second, it allows fairly simple distribution. Second, it allows fairly simple analyses that aid interpretation, particuanalyses that aid interpretation, particularly from a clinical perspective. We chose larly from a clinical perspective. We chose to calculate the absolute risk difference to calculate the absolute risk difference (i.e. the difference in proportion recovered). (i.e. the difference in proportion recovered).
The reciprocal of this measure is the The reciprocal of this measure is the number needed to treat (Sackett & Cook, number needed to treat (Sackett & Cook, 1995) . A positive value for a risk difference 1995). A positive value for a risk difference was given when the proportion recovered was given when the proportion recovered was greater in the intervention than in the was greater in the intervention than in the placebo group. For the small trials, exact placebo group. For the small trials, exact confidence intervals were calculated. confidence intervals were calculated. Otherwise, risk difference, 95% confidence Otherwise, risk difference, 95% confidence intervals and tests for heterogeneity were intervals and tests for heterogeneity were calculated using the Metan command calculated using the Metan command within Stata (StataCorp, 1999) . within Stata (StataCorp, 1999) .
RESULTS RESULTS
Using our search strategy, 753 potential Using our search strategy, 753 potential trials were initially identified and this numtrials were initially identified and this number increased as the search was updated ber increased as the search was updated quarterly until January 2001 to give a total quarterly until January 2001 to give a total of 919 trials. Forty studies were excluded of 919 trials. Forty studies were excluded from the review, in accordance with our from the review, in accordance with our published protocol (Stimpson published protocol (Stimpson et al et al, 2000) . , 2000). The search and identification of studies is The search and identification of studies is summarised in Fig. 1 . summarised in Fig. 1 .
Exclusions Exclusions
Fourteen trials were excluded from the Fourteen trials were excluded from the review as they included participants with review as they included participants with unipolar and with bipolar depression and unipolar and with bipolar depression and it was not possible to extract data on uniit was not possible to extract data on unipolar depression alone. In 11, participants polar depression alone. In 11, participants had been on antidepressant medication for had been on antidepressant medication for less than 4 weeks or at a dose of less than less than 4 weeks or at a dose of less than 150 mg imipramine or equivalent. Three 150 mg imipramine or equivalent. Three trials were abandoned on the grounds of trials were abandoned on the grounds of the randomisation. In one relevant trial the randomisation. In one relevant trial 2 8 5 2 8 5 Flowchart of progress through systematic review. RCTs, randomised controlled trials.
the randomisation had given rise to a the randomisation had given rise to a striking imbalance between the randomstriking imbalance between the randomised groups (Gitlin ised groups (Gitlin et al et al, 1987) . This , 1987) . This may well have resulted from the small may well have resulted from the small size of these trials ( size of these trials (n n¼16). One trial ran-16). One trial randomised participants to identical treatdomised participants to identical treatments ments (Antonuccio (Antonuccio et al et al, 1984) . A full list , 1984). A full list of excluded studies is available from the of excluded studies is available from the author upon request. author upon request.
Two crossover trials were also exTwo crossover trials were also excluded because it was impossible to extract cluded because it was impossible to extract data from the initial phase of the trial data from the initial phase of the trial before the crossover took place. One pubbefore the crossover took place. One published (Gagiano lished (Gagiano et al et al, 1993) and one un-, 1993) and one unpublished trial (source available from the published trial (source available from the author upon request) had to be excluded author upon request) had to be excluded as they did not describe the study with as they did not describe the study with sufficient detail to know whether the sufficient detail to know whether the inclusion criteria were met. One trial had inclusion criteria were met. One trial had to be excluded as data were not available to be excluded as data were not available on the subset of participants that were ranon the subset of participants that were randomly assigned to cognitive-behavioural domly assigned to cognitive-behavioural therapy (Barker therapy (Barker et al et al, 1987) . Two papers , 1987) . Two papers presented previously published results and presented previously published results and the duplicated results are not included in the duplicated results are not included in the review (Zohar the review (Zohar et al et al, 1985; Joffe & , 1985; Joffe & Singer, 1992) . Singer, 1992).
Included trials Included trials
Seventeen RCTs were identified, which inSeventeen RCTs were identified, which included a total of 645 participants. A variety cluded a total of 645 participants. A variety of different designs were adopted. After of different designs were adopted. After extracting the data we have chosen to extracting the data we have chosen to classify these designs according to the classify these designs according to the following four categories. following four categories. et al, 1999) and paroxetine (Tyrer , 1999) and paroxetine (Tyrer et al et al, 1987) . Two of these studies were also , 1987). Two of these studies were also crossover trials from which we extracted crossover trials from which we extracted data for the 2 weeks prior to crossover. data for the 2 weeks prior to crossover.
Antidepressant
Two of these trials (Klaiber Two of these trials (Klaiber et al et al, 1979; , 1979; Faravelli Faravelli et al et al, 1988) found a significant , 1988) found a significant advantage compared with placebo, despite advantage compared with placebo, despite their low statistical power. The largest of their low statistical power. The largest of these four trials randomised 47 subjects. these four trials randomised 47 subjects. In three trials that reported recovery rates, In three trials that reported recovery rates, none of the 38 subjects randomised to none of the 38 subjects randomised to placebo recovered (97.5% CI 0-9%). placebo recovered (97.5% CI 0-9%).
We excluded the results from the We excluded the results from the second phase of the crossover designs. second phase of the crossover designs.
Comparison of two active treatments Comparison of two active treatments
There were four trials that compared two There were four trials that compared two pharmacological agents (Table 2 ). The pharmacological agents ( ; and . paroxetine ; and olanzapine olanzapine v v. fluoxetine (Shelton . fluoxetine (Shelton et al et al, 2001) . , 2001). The venlafaxine The venlafaxine v v. paroxetine compar-. paroxetine comparison seems most relevant to current ison seems most relevant to current practice. The results of this trial did not practice. The results of this trial did not support the superiority of one or other support the superiority of one or other compound. Three of the performed compound. Three of the performed analyses led to a result that favoured analyses led to a result that favoured venlafaxine, but two of these did not adopt venlafaxine, but two of these did not adopt an intention-to-treat policy and most were an intention-to-treat policy and most were of marginal statistical significance. Almost of marginal statistical significance. Almost two-thirds of the subjects had been on a two-thirds of the subjects had been on a selective serotonin reuptake inhibitor preselective serotonin reuptake inhibitor previously. The Shelton study examined the viously. The Shelton study examined the policy of 'switching' between fluoxetine policy of 'switching' between fluoxetine and olanzapine as all the subjects had failed and olanzapine as all the subjects had failed to respond to fluoxetine. There was little to respond to fluoxetine. There was little information on previous medication for information on previous medication for the other studies. the other studies.
The comparison of an augmentation stratThe comparison of an augmentation strategy with a placebo seems the most relevant egy with a placebo seems the most relevant to clinical practice. Two trials of lithium as to clinical practice. Two trials of lithium as an augmentation agent (Zusky an augmentation agent (Zusky et al et al, 1988; , 1988; Joffe Joffe et al et al, 1993 ; Table 3 ) could be in-, 1993; Table 3 ) could be included and a meta-analysis performed. In cluded and a meta-analysis performed. In summary, lithium had a recovery rate by summary, lithium had a recovery rate by the end of the trial 25% greater than plathe end of the trial 25% greater than placebo (95% CI 2-49%), corresponding to cebo (95% CI 2-49%), corresponding to a number needed to treat of 4 (95% CI 2-a number needed to treat of 4 (95% CI 2-50). In all, there were only 50 patients in 50). In all, there were only 50 patients in the two lithium trials. There was no statisthe two lithium trials. There was no statistical evidence to support heterogeneity betical evidence to support heterogeneity between the trials ( tween the trials (w w 2 2 ¼0.6, d.f. 0.6, d.f.¼1, 1, P P¼0.44). 0.44). There were also three trials of pindolol There were also three trials of pindolol as an augmenter (Maes as an augmenter (Maes et al et al, 1996; Moreno , 1996; Moreno et al et al, 1997; Perez , 1997; Perez et al et al, 1999) reporting , 1999) reporting on 106 subjects, although one of these on 106 subjects, although one of these (Moreno (Moreno et al et al, 1997) did not report any , 1997) did not report any recoveries and therefore does not contrirecoveries and therefore does not contribute towards the summary estimate. bute towards the summary estimate. Overall, those given pindolol had an 8% Overall, those given pindolol had an 8% better recovery rate (95% CI 21% to better recovery rate (95% CI 21% to 7 76%) but this was not statistically signifi-6%) but this was not statistically significant. There was little evidence to support cant. There was little evidence to support any heterogeneity between the three pindoany heterogeneity between the three pindolol trials ( lol trials ( w w 2 2 ¼5.46, d.f. 5.46, d.f.¼2, 2, P P=0.07). Three =0.07). Three further trials also used this design but invesfurther trials also used this design but investigated different augmentation strategies tigated different augmentation strategies (Maes (Maes et al et al, 1996; Clifford , 1996; Clifford et al et al, 1999; Shelton Shelton et al et al, 2001) . , 2001). The overall recovery rate on placebo in The overall recovery rate on placebo in all the eight trials was 14 out of 107 suball the eight trials was 14 out of 107 subjects or 14.4% (95% CI 7.9-23.4%). jects or 14.4% (95% CI 7.9-23.4%).
Augmentation without a placebo Augmentation without a placebo
There were three trials that investigated There were three trials that investigated augmentation of an antidepressant but did augmentation of an antidepressant but did not compare with a placebo (Joffe & not compare with a placebo (Joffe & Singer, 1990; Fava Singer, 1990; Fava et al et al, 1994; Rybakowski , 1994; Rybakowski et al et al, 1999) (Table 4) . , 1999) ( Table 4 ).
Methodological quality of trials Methodological quality of trials
None of the trials would have met all the None of the trials would have met all the requirements of the CONSORT guidelines requirements of the CONSORT guidelines on reporting results of randomised trials on reporting results of randomised trials (Begg (Begg et al et al, 1996) . Two of the trials men-, 1996). Two of the trials mentioned that the random numbers were gentioned that the random numbers were generated with a computer program. Of the erated with a computer program. Of the ten trials that used a placebo, four menten trials that used a placebo, four mentioned that the placebos were identical in tioned that the placebos were identical in appearance to the active treatment. None appearance to the active treatment. None of the trials gave an indication of how the of the trials gave an indication of how the allocation of randomisation was conallocation of randomisation was conducted, and only one trial (Perez ducted, and only one trial (Perez et al et al, , 1999) described how the randomisation 1999) described how the randomisation was concealed. The two lithium trials menwas concealed. The two lithium trials mentioned that faked blood results were used to tioned that faked blood results were used to maintain blindness. maintain blindness.
Four studies (Joffe & Singer, 1990 ; Four studies (Joffe & Singer, 1990; Joffe Joffe et al et al, 1993; Perez , 1993; Perez et al et al, 1999; ) reported a power calcula-& Boyer, 1999) reported a power calculation, although one reported a power of tion, although one reported a power of 20%. Two trials recruited the exact num-20%. Two trials recruited the exact number of participants required by their power ber of participants required by their power calculations (Joffe & Singer, 1990; Perez calculations (Joffe & Singer, 1990; Perez et et al al, 1999) . One trial reported that the small , 1999). One trial reported that the small sample size recruited had limited the power sample size recruited had limited the power of their trial (Joffe of their trial (Joffe et al et al, 1993) and one trial , 1993) and one trial reported a power calculation incorrectly reported a power calculation incorrectly and did not report the sample size it reand did not report the sample size it required . The size quired . The size of the randomised groups ranged from a of the randomised groups ranged from a maximum of 62 participants to a minimum maximum of 62 participants to a minimum of 5 participants. Only 2 of the 17 trials of 5 participants. Only 2 of the 17 trials had a group with 25 or more subjects. had a group with 25 or more subjects.
Issues not addressed by studies Issues not addressed by studies
No RCTs were identified that assessed the No RCTs were identified that assessed the efficacy of psychotherapy and also met the efficacy of psychotherapy and also met the inclusion criteria. A number of trials of inclusion criteria. A number of trials of psychotherapy were excluded on various psychotherapy were excluded on various grounds (further details available from the grounds (further details available from the author upon request). author upon request).
No RCTs were identified that investiNo RCTs were identified that investigated increasing the dose of antidepressant, gated increasing the dose of antidepressant, or that compared switching to a new class or that compared switching to a new class Crossover design Crossover design with data with data extracted from extracted from period before period before crossover crossover (4 weeks) (4 weeks) HRSD, Hamilton Rating Scale for Depression; RDC, research diagnostic criteria. HRSD, Hamilton Rating Scale for Depression; RDC, research diagnostic criteria.
1. Results given as continuous measure: group HRSD score at baseline (s.e.) and at end of 4 weeks (s.e.). 1. Results given as continuous measure: group HRSD score at baseline (s.e.) and at end of 4 weeks (s.e.).
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Methodology Methodology
The systematic review used a thorough The systematic review used a thorough search strategy as part of the Cochrane search strategy as part of the Cochrane Collaboration. It is still possible, however, Collaboration. It is still possible, however, that some trials have not been identified that some trials have not been identified despite our efforts, and we would welcome despite our efforts, and we would welcome any information about trials, particularly any information about trials, particularly those that are unpublished. those that are unpublished. The major limitation of the review reThe major limitation of the review reflects the major weakness of the constituent flects the major weakness of the constituent trials. Almost all the studies were small in trials. Almost all the studies were small in size. Only 2 of the 17 trials had 25 or more size. Only 2 of the 17 trials had 25 or more subjects in a randomised group. A trial with subjects in a randomised group. A trial with 25 subjects in each group would be able to 25 subjects in each group would be able to detect the difference between 10% and detect the difference between 10% and 50% recovery with 80% power and 5% 50% recovery with 80% power and 5% significance. This is a large difference in significance. This is a large difference in outcome, much larger than the 14% differoutcome, much larger than the 14% difference reported in a recent meta-analysis of ence reported in a recent meta-analysis of fluoxetine fluoxetine v v. placebo (Bech . placebo (Bech et al et al, 2000) . A , 2000). A trial would have to randomise 219 subjects trial would have to randomise 219 subjects to each group to detect a difference to each group to detect a difference between 10% and 20% recovery with between 10% and 20% recovery with 80% power and 5% significance. All the 80% power and 5% significance. All the trials in this study were therefore severely trials in this study were therefore severely underpowered. Small trials can also lead underpowered. Small trials can also lead to a failure of randomisation, resulting in to a failure of randomisation, resulting in an imbalance between the randomised an imbalance between the randomised groups. We came across two studies where groups. We came across two studies where this had occurred and excluded them, but this had occurred and excluded them, but smaller degrees of imbalance might still be smaller degrees of imbalance might still be present. present.
Publication bias was impossible to Publication bias was impossible to assess as the trials studied such a diverse assess as the trials studied such a diverse range of interventions. It is usually asrange of interventions. It is usually assumed that systematic reviews of small sumed that systematic reviews of small trials are likely to be more susceptible to trials are likely to be more susceptible to publication bias than those that include publication bias than those that include larger trials. Even meta-analysis of larger trials. Even meta-analysis of moderately sized trials can provide biased moderately sized trials can provide biased conclusions (LeLorier conclusions (LeLorier et al et al, 1997) . , 1997). Since 1996, the CONSORT statement Since 1996, the CONSORT statement has provided guidance on the reporting of has provided guidance on the reporting of RCTs (Begg RCTs (Begg et al et al, 1996) . None of the 17 , 1996). None of the 17 studies, including those published after studies, including those published after the CONSORT statement, followed all the CONSORT statement, followed all aspects of its guidance. Trials with inaspects of its guidance. Trials with inadequate concealment of allocation are adequate concealment of allocation are associated with an increased estimate of associated with an increased estimate of benefit (Moher benefit (Moher et al et al, 1998) . Only one , 1998). Only one trial described how they kept the allocatrial described how they kept the allocation of subjects concealed from the clinition of subjects concealed from the clinicians involved in their care (Perez cians involved in their care (Perez et al et al, , 1999) . Overall, the trials did not meet 1999). Overall, the trials did not meet the current expectations concerning the the current expectations concerning the adequate reporting of randomised trials. adequate reporting of randomised trials.
Inclusion criteria Inclusion criteria
The World Psychiatric Association (1974) The World Psychiatric Association (1974) defined treatment-refractory depression as defined treatment-refractory depression as a failure to respond after a 4-to 6-week a failure to respond after a 4-to 6-week period on a recommended dose of antideperiod on a recommended dose of antidepressant. When planning the review and pressant. When planning the review and without prior knowledge of the included without prior knowledge of the included studies, we chose to set our inclusion criterstudies, we chose to set our inclusion criteria using a time limit of 4 weeks. This miniia using a time limit of 4 weeks. This minimum time limit was considered appropriate mum time limit was considered appropriate for a systematic review as it would ensure for a systematic review as it would ensure that we collected all relevant studies. It also that we collected all relevant studies. It also reflected the commonest clinical dilemma: reflected the commonest clinical dilemma: what to do next after lack of response to what to do next after lack of response to an antidepressant. We were surprised that an antidepressant. We were surprised that we excluded nine trials on the grounds that we excluded nine trials on the grounds that they defined treatment-refractory depresthey defined treatment-refractory depression using a time limit of 3 weeks. Because sion using a time limit of 3 weeks. Because the response to antidepressants can be the response to antidepressants can be delayed, we think this definition is rather delayed, we think this definition is rather too broad. We also excluded 14 trials too broad. We also excluded 14 trials on the grounds that they included both on the grounds that they included both patients with bipolar and with unipolar patients with bipolar and with unipolar depression. The management of depression depression. The management of depression in those with bipolar depression differs in in those with bipolar depression differs in some important respects from those with some important respects from those with unipolar depression. Antidepressants are unipolar depression. Antidepressants are used more cautiously in case this preciused more cautiously in case this precipitates a manic relapse. In the context of a pitates a manic relapse. In the context of a trial, a manic relapse might lead to an trial, a manic relapse might lead to an apparent 'improvement' in depression apparent 'improvement' in depression scores. Most people with established scores. Most people with established bipolar disorder would also be on a mood bipolar disorder would also be on a mood stabiliser such as lithium. stabiliser such as lithium.
Design of trials Design of trials
We excluded the second phase of crossover We excluded the second phase of crossover designs as these are inappropriate for antidesigns as these are inappropriate for antidepressant trials in which subjects may depressant trials in which subjects may recover. Antidepressants have a delay of recover. Antidepressants have a delay of 2-3 weeks before they take effect and so 2-3 weeks before they take effect and so short periods before crossover are uninforshort periods before crossover are uninformative, as acknowledged by Tyrer mative, as acknowledged by Tyrer et al et al (1987 Tyrer et al et al ( ). (1987 .
We identified four different designs in We identified four different designs in our included studies. Four studies comour included studies. Four studies compared an antidepressant pared an antidepressant v v. a placebo, thus . a placebo, thus investigating removing an antidepressant investigating removing an antidepressant agent and replacing with placebo. Because agent and replacing with placebo. Because some subjects with 'treatment-refractory some subjects with 'treatment-refractory depression' will have had a partial redepression' will have had a partial response, removal of antidepressant would sponse, removal of antidepressant would be expected to lead to a worsening of sympbe expected to lead to a worsening of symptoms. Two of the four trials using this toms. Two of the four trials using this design found improved recovery on active design found improved recovery on active antidepressant. These results argue against antidepressant. These results argue against stopping antidepressant medication in stopping antidepressant medication in those who have not had a good response. those who have not had a good response.
Four trials compared two active treatFour trials compared two active treatments. This also investigates switching to ments. This also investigates switching to another antidepressant following failure to another antidepressant following failure to respond. However, the most relevant trial respond. However, the most relevant trial , which compared , which compared venlafaxine and paroxetine, included subvenlafaxine and paroxetine, included subjects that had been exposed to either jects that had been exposed to either selective serotonin reuptake inhibitors, triselective serotonin reuptake inhibitors, tricyclics or both. To study the policy of cyclics or both. To study the policy of switching to a new antidepressant, a more switching to a new antidepressant, a more informative design would be to recruit subinformative design would be to recruit subjects who had been treated with a single jects who had been treated with a single class of antidepressant and then randomise class of antidepressant and then randomise to either staying on the same class of antito either staying on the same class of antidepressant or switching to an alternative depressant or switching to an alternative class. This design was used (Shelton class. This design was used (Shelton et al et al, , 2001 ) to compare remaining on fluoxetine 2001) to compare remaining on fluoxetine with switching to olanzapine. with switching to olanzapine.
Augmentation Augmentation
The most informative designs were those in The most informative designs were those in which an augmenting agent was added to which an augmenting agent was added to antidepressant medication and compared antidepressant medication and compared with a placebo and antidepressant. Our with a placebo and antidepressant. Our finding that 14% (95% CI 8-23%) of the finding that 14% (95% CI 8-23%) of the placebo group recovered emphasises the neplacebo group recovered emphasises the necessity of a placebo comparison for studies cessity of a placebo comparison for studies of augmentation. of augmentation.
The two lithium trials were small, The two lithium trials were small, with only 50 patients in all, and treated with only 50 patients in all, and treated subjects for 1-2 weeks, a relatively short subjects for 1-2 weeks, a relatively short duration. Although there was a statistically duration. Although there was a statistically 2 9 0 Begg, C., Cho, M., Eastwood, S., Begg, C., Cho, M., Eastwood, S., et al et al (1996) (1996) Improving the quality of reporting of randomized Improving the quality of reporting of randomized controlled trials. In the absence of good evidence, clinicians will have to rely upon their own clinical judgement in deciding upon treatment. judgement in deciding upon treatment.
LIMITATIONS LIMITATIONS
& & Like all systematic reviews it is limited by the quality of the constituent studies.
Like all systematic reviews it is limited by the quality of the constituent studies.
& & The main conclusion is that further research is required as the findings are not The main conclusion is that further research is required as the findings are not strong enough to support any clinical guidance. strong enough to support any clinical guidance. 
